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ABSTRACT
DEVELOPMENT AND TESTING OF A SIMULATED CLOSED LOOP DRUG
DELIVERY SYSTEM FOR CHF PATIENTS UNDER MILRINONE
ADMINISTRATION
by
Runa Shah
The purpose of this thesis project is the development and testing of a simulated closed
loop drug delivery (CLDD) system that consists of a pharmacokinetic, physiological, and
feedback-controlling model. The focus of this study is on the control of milrinone
infusion to maintain cardiac output at desired setpoint range for patients suffering from
congestive heart failure (CHF). The simulated CLDD system is written in VisSim
dynamic simulation language for an IBM-compatible PC.
Milrinone pharmacokinetics are represented by a three compartment model. The
physiological model consists of the cardiovascular system model linked to the
pharmacodynamic submodel of milrinone. The feedback-controlling model consists of a
cascade controlling mechanism incorporating a PID controller.
Validation of system dynamics was performed by comparison of simulated results
of the loop model (pharmacokinetic and physiological model) to available experimental
data. Pharmacokinetic and hemodynamic responses showed that the behavior of the
simulated open loop model was similar to that of CHF patients under milrinone
administration.
The addition of the feedback-controlling model to the open loop model resulted in
the development of the CLDD system. Performance of the cascade controller was
optimized with tuning of PID controller. A two-hour control performance was monitored
as the CLDD system underwent the following situations: (1) target CO was modified

(transient response), (2) perturbation was incorporated as circulatory vessel resistances
were changed, and (3) randomization of system parameter was achieved by varying the
elimination rate constant. Onset delay, time taken for controller to bring CO within set
boundaries, and percentage overshoot of cardiac output from target were the underlining
results analyzed in understanding the performance of the controller.
Aside from some minor refinements, the overall performance of the controller
showed it to be robust in responding to the changes in the system by adjusting milrinone
infusion so that cardiac output could track to the setpoint. The simulated CLDD system
as a whole was observed to correctly represent clinical automated drug delivery. The
results of the simulated controller also lead into the possibility of developing an
automated control milrinone infusion system for maintaining cardiac output for CHF
patients.
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CHAPTER 1
INTRODUCABKGROUND
As the society moves into the next millennium, the use of computers in daily activities
has advanced. Many responsibilities formerly performed by humans are now in the
command of computers. The use of computers reduces problems caused by human error.
The focus of this thesis is the administration of drugs by the use of computers in the field
of medicine.

1.1 Introduction
Traditionally delivery of drugs has been empirically regulated by the clinicians based on
the known physiological effects and observed efficacy and toxicity. Now with the
advances in closed loop technology, the computer control can be used to administer drug
in order to maintain a physiological response. The use of closed loop systems provides
two main advantages: (1) clinical personnel are relieved of some of the mundane and
repetitive monitoring and infusion adjustment tasks that are done automatically by the
closed loop system and (2) this system provides tighter regulation of a physiological
variable at a desired level than can be accomplished with manual methods.[1] Since this
task is now the responsibility of the computer, the clinician can better concentrate on
other duties. This can be considered as a third non-direct advantage for the use of closed
loop drug delivery (CLDD) systems.
This research concentrates on the design and evaluation of a simulated closed
loop drug delivery system for the infusion of milrinone. Milrinone is a second generation
drug used to increase cardiac contractility in congestive heart failure patients in order to
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increase cardiac output during surgery. The physiological response that is monitored is
cardiac output. The primary focus is the design of a CLDD system for congestive heart
failure patients. Thus a closed loop feedback system is designed to control the infusion
of milrinone in order to maintain the cardiac output at a desired target for patients
suffering from congestive heart failure.
The following sections document available research studies done on drug delivery
control system, proposes a closed loop system for monitoring and administering drug,
and presents results of computer simulation of the closed loop response. It also explains
VisSim, the simulation language used in this research. Additional discussion focuses on
the appropriateness of the use of milrinone for congestive heart failure patients.

1.2 Control Systems
Much of the work with closed loop system control has focused on arterial pressure
control in cardiac surgery patients. Systems using a variety of drugs for both
hypertension and hypotension have been reported to rapidly and faithfully control arterial
pressure under research conditions. Martin [2] designed a multiple-model adaptive

Figure 1.1 Diagram representation of desired blood pressure response using MMAC
control
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Figure 1.2 Block diagram of control scheme given a known plant

controller (MMAC) for the control of blood pressure using sodium nitroprusside (SNP).
MMAC is a control strategy that can identify and then adapt to changing characteristics.
Lainiotis [2] introduced the concept of multiple model adaptive control. MMAC uses a
finite range of models, assumed in this case to be reasonable representations of possible
patients, from which to identify the patient. An automated drug infusion system for
blood pressure should have certain performance characteristics. These include, a 20
percent settling time of less than 10 min, a maximum overshoot of less than 10 mmHg,
and a steady-state error within ±5 mmHg, Figure 1.1. Along with these performance
characteristics, the controller also has clinical constraints, as well. The first of the
clinical constraints is the maximum allowable infusion rate. The basic controller is
shown in figure 1.2. The concept of the controller is that a given a transfer function or
known plant, the desired closed-loop responses can be achieved via pole-placement and
state-variable feedback. The series compensator in Figure 1.2 was obtained using this
method. The proportional plus integral (PI) unit was used to achieve a steady state error
of ±5 mmHg with no dc offset. To remove the effects of infusion delay a predictor model
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was used. A low-pass filter was included to minimize the effects of noise. To help
maximize patient safety, two nonlinear units were built into the system. The first, F1, is
used to turn off the infusion of SNP if patient's blood pressure drops too low. The other
nonlinearity, F2, limits the actual infusion rate according to the maximum allowable
infusion rate. Numerous tests, including variation of the gains, time constants, and
infusion delays were performed to demonstrate the robustness of the controller. The
results showed that the controller controlled wide ranges of patient characteristics. In all
cases, the desired performance characteristics or better (20 percent settling time < 10 min,
overshoot < 10 mmHg, and steady-state error within ± 5 mmHg) were achieved. In 35
cases, the average settling time was 2.6 min and the average overshoot was 2.4 mmHg.
Furthermore, steady-state error of blood pressure was within the boundaries specified.
Patient safety was also maintained in all cases. In conclusion, the controller satisfied the
desired performance characteristics while maintaining patient safety. [2]
Additional studies on closed loop drug delivery focus on the simultaneous control
of blood pressure and cardiac output. Yu [3] has applied the MMAC concept to design a
controller to simultaneously regulate MAP and cardiac output in congestive heart failure
(CHF) subjects by adjusting the infusion rates of sodium nitroprusside (SNP), a
vasodilator, and dopamine, a positive isotropic agent, respectively. Instead of the
conventional PI and PID controllers utilized in previous single-input, single-output
MMAC designs, a model predictive controller (MPC) was used for each model subspace.
The MPC is comparatively simpler to tune than the PI and PD controllers in a
multivariable environment. The controller was evaluated on laboratory animals that were
either surgically or pharmacologically altered to exhibit symptoms of CHF. Although the
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design called for the regulation of both outputs, a tighter regulation of MAP was sought
(±10 mmHg). The transient response should have a settling time of less than 10 min for
MAP and 20-25 min for CO. A total of 16 runs were performed for each test. Before the
start of each run, baseline values for each output were obtained. Each trial started with a
step command for both outputs and continued for 80 minutes. The initial step always
asked for an increase in CO while MAP could either be increased or decreased.
Controller performance to the initial step commands is summarized in Table 1.1. The
response time is the time needed for the output to come within 5 mmHg of the steady
state setpoints for MAP and the time taken to climb within 5 ml/min/kg of the steady
state setpoint flow for CO. The response time of the outputs were within the settling
times specified in the design. The mean MAP undershoots less than 10 mmHg.

Table 1.1 Summarizes the performance of the MMAC design using MPC controller in
maintaining MAP and CO, n = # of patients
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Large overshoots were sometimes observed with step command increases in CO, but
there was no design constraint on this value. As shown in the table the magnitude of the
step up in pressure is significantly smaller than that of the step down because
considerable increase in pressure could augment the load on the heart. The results
outlined in Table 1.1 show that the controller is robust in regulating both physiological
outputs at the desired levels.
Another point of interest in CLDD systems are the studies done to compare closed
loop control with nurse or anesthesiologist control. Most of the studies report superior
performance by closed loop control systems. [4] Stern performed a study that compared
the human performance with that of a controller in the control of arterial pressure by
adjusting the infusion of SNP. The automated system used a computer-controlled
Watson-Marlow infusion pump to infuse SNP, while the anesthesiologist administered
the drug through an IVAC 530 infusion pump. The anesthesiologist had more than ten
years experience, which included the management of patients during open-heart surgery.
The protocol consisted of requiring the computer and the physician to perform identical
control tasks. Only those control tasks that were part of the comparison were included in
the analysis. A comparison pair consisted of one automated control and one manual
control performed under identical conditions in the same animal. The target MAP was
generally achieved within the required 5 min by both controllers. The mean steady-state
error was below 5 mmHg, standard deviation of the steady-state pressure was less than 2
and 3 mmHg for the computer and physician, respectively. The mean SNP infusion rate
for the two controllers was below the recommended maximum infusion rate of 3mg/kg/h.
The controller proved to perform as well, if not better, than the physician. Note that the
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control task performed by the anesthesiologist in this work is by no means typical of the
clinical use of SNP. The anesthesiologist devoted his full concentration to controlling
blood pressure as accurately as possible, knowing that his performance was monitored.
In clinical situations, many other tasks would also compete for the physician's attention,
leading to a likely degradation of his performance as a controller of blood pressure. Some
of the anesthesiologist's functions are as follows: (1) control ventilation, (2) monitor vital
signs such as ECG, pulse, and temperature, (3) continue administering anesthetics and
drugs to maintain homeostasis, (4) give blood or other blood products, (5) titrate
anesthetics to the level of surgical stimulation, (6) reverse muscle relaxation in the end of
surgery, (7) and finally extubate the patient. Thus the performance on the closed loop
control would be superior. Sheppard and Kouchoukos reported that closed loop
regulation of arterial pressure has contributed to a 50% reduction in the length of stay in
the postcardiac surgery ICU with some associated cost savings.[1]

1.3 Simulation Studies on Control Systems
Development of a clinically useful closed loop drug delivery system is both time
consuming and expensive. Thus making simulation studies an attractive alternative in the
development of a closed loop drug delivery system. Through the use of simulation
studies both time and cost can be reduced. This approach allows for the evaluation of the
controller's performance over a complete spectrum of patient population. Another
advantage of simulation studies is repeatability. Woodruff [5] designed a simulator for
closed loop cardiovascular therapy. The simulator contains mathematical models that
relate the infusion rates of specific drugs to dynamic changes in physiological
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parameters. The simulator consists of four different types of models, a nonlinear
pulsatile-flow cardiovascular model, a physiological regulatory model of baroreceptors, a
pharmacokinetic model, and a pharmacodynamic model for each drug. Its control
mechanism is multiple model based. The nonlinear, pulsatile-flow model of the
cardiovascular system consists of five compartments, left ventricle, systemic arteries,
capillaries, systemic veins, and a low-pressure compartment. The regulatory model
attempts to maintain a homeostatic pressure by adjusting arterial resistance, venous tone,
ventricle contractility, and HR. The pharmacokinetic and pharmacodynamic models
were developed from experimental tests of the drug. To validate that this simulator was
an appropriate representation of clinical situations that patients undergo, a series of
verification studies were performed. These studies included comparisons of simulator
results to published data (both animal and clinical). The multiple-model simulator was
further validated with a series of dynamic simulation studies. The study included
evaluating the ability of anesthesiologists, ranging from first year resident to full
professor, to manually control the drug using the simulator. All participants in the study
concluded that the simulator responded similarly to drug administration, as a patient
would have. Additional study on the simulator included using it to compare the relative
abilities of the closed-loop drug delivery device and clinicians to induce and maintain
deliberate hypotension. The results were that there was no statistical difference between
the experienced clinician and the closed-loop device in inducing and maintaining
deliberate hypotension. This simulator has been used in the design and validation of both
MMAC and multiple-input-multiple-output control advance moving-average controller
(CAMAC). It is the use of simulation studies that allows for the development of the
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closed loop system. The simulation language used in the design and testing of the CLDD
system in this paper is VisSim.

1.4 VisSim Simulation Language
VisSim or visual simulation is appropriate software for this research.

VisSim is a

simulation package for developing continuous, discrete, multi-rate and hybrid system
models and running dynamic simulations on IBM PCs and compatibles. VisSim
incorporates a graphics user interface that is used to create diagrams of the systems being
simulated. Each model consists of a collection of components or blocks connected by
flexwires. These blocks can perform many kinds of activities such as evaluating a
mathematical function, generating a random value, performing an arithmetic or logical
test, and producing different forms of animation. There are two types of blocks within
VisSim: (1) standard blocks, and (2) compound blocks. Standard blocks include (1)
Arithmetic blocks, (2) Integration blocks, (3) Time Delay blocks, (4) Boolean blocks, (5)
Linear System blocks, etc. A compound block, on the other hand, is a combination of
one or more standard blocks. The purpose of a compound block is to make the block
diagram more organized, less confusing, and more presentable. Other simulation studies
involving CLDD systems have used Mathlab, C, or C++, but this research looks into the
power of VisSim to regulate cardiac output via the infusion of milrinone for CHF
patients.
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1.5 Congestive Heart Failure

Congestive heart failure (CHF) is a condition characterized by the loss of contractile
force by the cardiac muscle fibers leading to an inability of the heart to maintain cardiac
output sufficiently in order to meet the requirements of the metabolizing tissues. [6]
Therefore there is a transudation of fluid into the tissues giving rise to congestion and
oedema at various sites. It is the weakening of the heart muscle that prevents the heart
from pumping blood effectively. Depending on the degree failure, the patient has limited
exercise tolerance, fatigue or effort dyspnoea. CHF usually occurs as a late manifest of
most forms of heart disease. Other causes include low flow, ishemia, defective valve,
pulmonary embolism, infection, anemia, arrhythmia, hypertension, and physical, dietary,
environmental and emotional excesses. Because the heart is not strong enough to pump
blood sufficiently, agents with positive inotropic activity are indicated in the treatment of
CHF.
The main final pathway for control of cardiac output is via a group of receptors
linked to a G protein-adenylate cyclase (RGC) complex at the sarcolemma. This
complex has two distinct effects: it directly opens slow calcium channels in the plasma
membrane, and it activates the production of the intracellular second messenger, cyclic
adenosine monophosphate (cAMP), from adenosine triphosphate (ATP). The results of
these effects include (1) more force development and (2) increased velocity of
shortening.[7] In the chronically failing heart there are possible defects in some of the
receptors. High energy phosphates are also reduced, therefore increasing the dependence
on inotropic support from the neurohumoral system to maintain cardiac output.
Phosphodiesterase (PDE) inhibitors offer a rational therapy for CHF patients and thus
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promote an increase in cAMP and so increase cardiac output.[8] The PDE inhibitors are
a class of bipyridine compounds that increase the inward calcium flux during the action
potential (mode of action opposite to that of the calcium blockers), effect the intracellular
movements of calcium, and have been shown to inhibit phosphodiesterase.
Phosphodiesterase is the intracellular regulator of cAMP and cGMP by degrading these
second messengers to 5 'AMP 5 'GM?, respectively. Milrinone is a PDE III inhibitor
that produces positive inotropic and vasodilator effects.

1.6 Milrinone
Milrinone and amrinone are the two selective PDE inhibitors approved for clinical use in
the United States The chemical structures of the two PDE inhibitors are shown in Figure
1.3. Both bipyridine compounds inhibit phosphodiesterase enzyme resulting in an
increase of cAMP and increased Ca to the myocardium. Milrinone is the derivative of
amrinone, with approximately 10 to 75 times greater positive inotropic potency, and
separate direct vasodilatory properties. Also, milrinone produces the same hemodynamic
changes without causing the noncardiac adverse effects, such as thrombocytopenic
effects, fever and gastrointestinal effects as observed with amrinone. [6] Additional
studies conclude similar findings. Hasegawa [9] made the following conclusions from
his study of the drug: (i) Patients receiving milrinone have tolerated the drug well.
(ii) Milrinone therapy has not been complicated by the noncardiac side effects. (iii) In
fact, one patient who had developed fever and thrombocytopenia while taking amrinone
tolerated milrinone therapy without recurrence of these complications.
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Figure 1.3 Chemical structure of (a) amrinone and (b) milrinone, the 2-methyl, 5carbonitrile derivative

In addition to these advantages this drug increases myocardial contractility in
CIE patients without increasing myocardial oxygen consumption. [10] Aside from
milrinone's comparative studies with amrinone, milrinone has also been evaluated with
other inotropic and vasodilator agents including dobutamine, nitroprusside, and
captopril.[6] When dobutamine infusion was compared with milrinone, both drugs
produced similar sustained improvement in cardiac index. But dobutamine infusion
resulted in an increase in heart rate to a greater extent than did milrinone, thereby
increasing myocardial oxygen demand that was not evident with milrinone. When
compared with nitroprusside, milrinone increased cardiac output to much greater extent
than did nitroprusside infusions. In a comparative study with captopril, it was observed
that milrinone increases cardiac index to a greater extent than captopril. Young [6]
concluded that milrinone shows evidence of producing more sustained and significant
improvements in hemodynamic measurements. Therefore, milrinone is the selected drug
used in this research.

CHAPTER 2
CLOSED LOOP MODEL
VisSim simulation study of the CLDD system consists of three main interfacing models,
milrinone pharmacokinetic (PK) model, physiological model, and feedback-controlling
model. The purpose of this research includes the development of the PK model for
milrinone and feedback-controlling model as well as testing of the CLDD system
(consisting of all three models).

2.1 Physiological Model
The physiological model, designed in previous research, is the mathematical
representation of the physiological response of the body to the drug infusion. The
physiological model consists of the cardiovascular system model linked to the
pharmacodynamic submodel of milrinone. [11]
The cardiovascular system [12] is composed of twenty compartments which
includes the left and right ventricles, the systemic and pulmonary circulation as shown in
Figure 2.1. In this model the arterial system is represented by one or more interconnected
elastic reservoirs, the Windkessel approach. A Windkessel compartment is described by
a single ordinary differential equation. A two-element Windkessel model, which consists
of a resistance (R) and compliance (C) represents each compartment. The relationship
between the blood flow and blood pressure in a compartment is represented by Equation
2.1.
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Figure 2.1 Schematic diagram of the cardiovascular system used in this work
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where:
F i = blood flow out of compartment i
P i = blood pressure in compartment i
Pi+1 = blood pressure in compartment i+1
Ri+ 1 = vessel resistance of compartment i+1

The pressure P in a compartment is related to the compartment's volume V by a
compliance term. Equation 2.2

Finally the change of volume (dV/dt) is represented as the difference of the inflow (Fi n )
and outflow (F ay.) by Equation 2.3. According to the law of conservation of mass, this
equation describes the variation of blood flow.

The model also accounts for autoregulation of blood flow and baroreceptor reflex
regulation of arterial pressure. Autoregulation is the changing of local resistance to blood
flow through metabolic and myogenic mechanisms, which causes a match between
oxygen supply and demand for any tissue or organ. To maintain the equilibrium between
supply and demand of oxygen, blood flow is adjusted. Baroreceptors are located at the
carotid sinuses and aortic arch. Of the two locations, the carotid receptors are more
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sensitive to pressure than are the aortic arch receptors. Therefore the carotid sinus
receptors are considered in the physiological model. Baroreceptors act through neural
pathways to alter heart rate, contractility and peripheral resistance to return sudden
changes in blood pressure to normal "set point".[12] Congestive heart failure was
simulated by reducing ventricular maximum systolic elastance to 40% of normal.[11] An
in depth study of this model can be found in Gu.
The pharmacodynamic (PD) model for milrinone was represented by changes in
vascular resistance, cardiac contractility, and heart rate. The experimental data and
corresponding equations used in the PD submodel were obtained from
www.amwtech.com/cardiac. Approximate drug concentration-heart rate relationships
were obtained through the use of linear relationships.[11]
The physiological model, linking of the cardiovascular model to milrinone PD
model, is used to predict hemodynamic responses and ischemic potential of milrinone
therapy in simulated patients with CHF. The input of the physiological model is the
milrinone plasma concentration (ng/ml) and the output that is the focus is the cardiac
output (CO).

2.2 Pharmacokinetic Model
The PK or pharmacokinetic model describes the uptake, distribution, and elimination of
the drug (in this case milrinone) as defined by Hull [13]. Pharmacokinetics is what the
body does to the drug. The essentials of pharmacokinetic theory include compartmental
approaches, which consists of the use of compartments.
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Figure 2.2 Pharmacokinetic compartment models for milrinone.(a) 2-compartment (b) 3compartment.

A compartment is defined as an apparent volume of distribution that behaves as a single
physical and mathematical entity. When placed in the compartment, any quantity of drug
is assumed to be completely and instantaneously distributed throughout the apparent
space.[13] Milrinone has been described both as a two compartment PK model and as a
three compartment PK model. (Figure 2.2) Butterworth [14] and Bailey [15]
independently performed a study that compared two compartment analysis to a three
compartment analysis for PK model of milrinone. Both studies worked with cardiac
patients. The two studies concluded that a three-compartment model was found to be a
better description of the data for majority of patients than the two-compartment model.
Therefore a three compartment PK model for milrinone is used here. The first or central
compartment represents the blood, and is used to provide drug concentration in the
plasma. The remaining two compartments represent the shallow peripheral compartment
(1) and deep peripheral compartment (2).[13] The two compartments are basically
storage areas of fat, tissue, etc. The three compartment model is written in terms of rate
constants (Figure 2.2b), which represent the rate of drug distribution from one
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compartment to the other. The rate constants were calculated from the known volumes

where:
Cln = clearance of compartment n
Vn = volume of compartment n

knm = the rate of drug elimination from compartment n to compartment m

The concept of clearance is a measure of the eliminational efficiency, and is defined as
the rate of drug flow per unit concentration. Hull [13] explains the relationship between
volume and clearance using a bucket of water analogue. Hulls analogue is as follows.
Clearance of water from the bucket is a way of describing the size of the outflow pipe;
the wider the pipe, the greater the clearance. Clearance from this system can be defined
as the flow rate per unit water level. Since any volume in the bucket can be re-stated as
the product of cross-sectional area and difference in water level, the flow rate term can be
restated as the product of the cross-sectional area and the rate of decline of water level at
some stated time. Rewriting the expression for clearance (C1), Equation 2.9 is obtained.
Cl = Area ( Rate of fall/Water level )

(2.9)
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The rate constant k of any exponential change can be defined as the ratio of rate
of change at any time to the magnitude of the variable at that time; in this case the rate of
fall divided by the water level. Furthermore, one observes that the cross-sectional area of
the bucket represents the apparent volume of distribution Vd. Therefore Equation 2.10 is
obtained.

With the rate constants being known, a differential equation approach was used to
describe the three compartment PK model. [16] This notation describes the rate of change
of drug concentration following drug administration.

where:
xn (t) = concentration of drug in compartment n at time t
dxn (t)/dt = rate of change of drug in compartment n at time t
kab = rate constant for drug transfer from compartment a to compartment b
k10 = elimination rate constant from compartment 1
Kt) = the dosage of drug into compartment 1 at time t
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Each of the three differential equations simply sets out a pattern of drug flows; inputs are
positive and outflows are negative. The rate of drug movement in or out of the
compartment 1 is simply the resultant of the two processes. Observing Equation 2.11:
concentration x i in central compartment is emptying into compartments 1 and 2
according to the rate constants k 12 and k 1 3, respectively. While concentration x 2 and x3
are emptying back into the central compartment according to rate constants k21 and k31
respectively. Finally the third term is simply the elimination route, with drug leaving the
model according to the concentration of the drug in compartment 1, xi, and rate constant
k 10 . Equation 2.12 and 2.13 sees the same process of inflow minus outflow.
Transferring these equations into VisSim block diagram was very simple. The
availability of the integrator block allowed the writing of the differential equations. The
integrator block performs numerical integration on the input signal using the integration
algorithm. The equations were completed in VisSim format by the use of arithmetic
blocks. The block diagram of the PK model can be seen in Figure 2.3. This figure shows
three summation blocks. The first summation block produces dxn(t)/dt, which is the
resultant of the two process, inflow and outflow of drug. This is then fed into the
integrator block, thus producing x„, drug concentration in compartment n. The input into
the PK model is the milrinone dose and the output that is of concern is the drug
concentration (ng/ml) in the first or central compartment, xi.
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Figure 2.3 VisSim block diagram of three compartment pharmacokinetic model for
milrinone
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2.3 Feedback Controlling Model
The third model of the closed loop system is the feedback-controlling model. This is the
brain of the CLDD system that decides on the milrinone dose so that desired set points
are met for the cardiac output The feedback-controlling model consists mainly of a
cascade controller. The cascade controller contains two controllers, the output of the first
controller is input into the second controller before it is feed back into the rest of the
system. The first controller is a PID controller. The second controller contains
commands and conditions of how PID output is feed back into the milrinone PK model.
The rest of the feedback-controlling model contains additional commands of when the
PID controller is implemented. The importance of the second controller will be made
obvious in later chapters.
PID, short for Proportional-Integral-Derivative, controllers are known as the
"bread and butter of control engineering", the most common control algorithm.[17] PID
controllers are used in all kinds of control systems. This controller has several important
functions, (1) provides feedback, (2) has the ability to eliminate steady-state offsets
through the integral action, (3) anticipate the future through the derivative action, (4) and
can cope with actuator saturation. There have been many systems designed to control
physiological variables automatically, but the majority use some form of PID control.[4]
PID controllers often work well and are simple to implement. In fact Hao Ying, Ph.D. of
the University of Texas-Medical Branch and control professor states that PID is very
appropriate controller for closed loop drug delivery because (1) 90% of controllers used
are PID or some form, (2) PID controllers are very simple to use, and (3), it is effective.
Dr. Ying's [18] study with fuzzy control of mean arterial pressure in postsurgical patients
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with sodium nitroprusside infusion uses a nonlinear PI controller. Fuzzy controllers are
linguistic if-then-rule based and can be designed using control operators' knowledge and
experienced about processes. A fuzzy controller can thus be regarded as an expert
system employing fuzzy logic for its reasoning. Fuzzy controllers, being generally
nonlinear, provide an alternative means to solve time-delay, nonlinear and time-variant
control problems whether mathematical models of processes involved are available.
Biological systems such as the human body involve time-delay, nonlinearity and timevariance. Results of Dr. Ying's research with this controller revealed that the
performance of the fuzzy control SNP delivery was clinically acceptable and it will
perform well for most patients. Therefore making the selection and use of PID control
algorithm appropriate for this research.
The textbook version of the PID algorithm [17] has the following form:

where u is the control variable (milrinone dose) and e is the control error (e r — y),
which is the difference between set point r (target cardiac output) and measured value y
(true cardiac output). The dosage is the sum of the three terms: the P-term (which is
proportional to the error), the I-term (which is proportional to the integral of the error),
and the D-term (which is proportional to the derivative of the error). K is the gain or
proportional gain of the controller, Ti the integration time, and Td the derivative time.
The proportional action is simply proportional to the control error, e. The main function
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Figure 2.4 VisSim block diagram of PID controller

of the integral action is to make sure that the process output agrees with the set point in
steady state. The purpose of the derivative action is to improve the closed loop stability
Transferring the textbook version of the PID algorithm to VisSim block diagram
was very simple. In the VisSim toolbox folder there are available block diagrams of
several controllers, one of them being PID control. The VisSim block diagram of the
PID controller is obtained by use of integrator blocks and simple arithmetic blocks as
shown in Figure 2.4. From the figure, target cardiac output and the cardiac output are the
setpoint and feedback inputs into the PID controller, respectively. The difference of
these two signals, the error, becomes part of the proportional, integral, and, derivative
term. The PID output is the summation of the proportional of the error, integral of the
error, and derivative of the error terms as seen in the block diagram. The PID controller
is used to control both steady state accuracy (using the integral and proportional terms)
and transient response (using the derivative and proportional terms). The limitations of
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this controller are (1) time constant > 0 and (2) simulation stepsize must be greater than
the time constant for stability.
In addition to the PID controller, the feedback-controlling model also contains
block diagram that controls when PID is implemented into the rest of the system. To
understand how this is done, lets first discuss at the compound block called
hysteresis. [1 9]
The hysteresis block provides ON/OFF output depending on some input signal
and its set limits. In other words the hysteresis block is a switch for the PID controller.
The input signal, upper limit, and lower limit are set to the error of the cardiac output, 5%
of target cardiac output, and 2.5% of target cardiac output respectfully. Given these set
limits, the function of the block is as follows. Block output is ON (1) when the error is
above the upper limit. The compound block continues to output ON until the error
reaches the lower limit from above. Once lower limit is exceeded from above the output
is switched to OFF(0). The output is OFF until the upper limit is exceeded from below.
The detailed block diagram of the hysteresis compound block is shown in the appendix,
Figure Al.
The input into hysteresis is the error, the output is either 1 (ON) or 0 (OFF). This
output is feed into two distinct merge blocks. The VisSim merge block is an equivalent
of the if-then-else algorithm of text based languages.

The merge block examines x 1 , Boolean signal, to determine the output signal y. If the
Boolean signal is true (|x1| >= 1) than y x 2 , but if the Boolean signal if false (kJ] <1),
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Figure 2.5 VisSim block diagram of the feedback-controlling model. The blue VisSim
blocks represent compound blocks. A compound block is a combination of one or more
standard VisSim blocks.
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than y = x3 as seen in equation 2.15. The first merge block decides whether to enable or
disable the PID controller. Looking at Figure 2.5 that shows VisSim block diagram of
the feedback-controlling model, the following can be observed. The first merge block
either assigns the cardiac output or target cardiac output value to the temp CO variable
block depending on the hysteresis block output. The temp CO value is feedback into the
PID controller. The PID controller is enabled when temp CO cardiac output. But the
controller is disabled when temp CO = target cardiac output because zero error is forced
on the PID controller therefore providing zero output. The second merge block functions
as follows. Again the hysteresis output is the Boolean signal. Here a new variable block
is introduced, temp dose. Temp dose is assigned the new MD output if a value of 1 is
feed into Boolean signal; temp dose is assigned the previous HD output if Boolean
output is 0. The delay block is attached to the output of second merge block because
temp dose is continually assigned a new value each simulation step size. VisSim updates
or increments variables by use of delay blocks. The two merge blocks work together
either to enable the HD controller therefore assigning temp dose the new PID output
value (incrementing dose), or to disable the PID controller therefore assigning temp dose
the previous PID output value. The value of temp dose is then feed into the second
controller.
The second controller plays a very vital role in performance of the cascade
controller as a whole. A detailed description of the second controller is as follows. The
value of temp dose that is fed into this controller can take one of the two available paths
before entering the PK model as milrinone dose. The first path interprets this input as a
bolus dose. The second path interprets the value of temp dose as an infusion rate. Given
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the case that a bolus is implemented, than it can either be a large bolus or a small bolus.
The large bolus has upper limit of 50 µg/kg given the condition that the error is above
10% of target cardiac output (Error > 10% target CO). Target cardiac output is given as a
50% increase in baseline CO, therefore target CO is 4587 ml/min. The small bolus has
an upper limit of 10 µg/kg given that the error falls above 5% of target CO and below
10% of target CO (5% target CO < Error < 10% target CO). The second path which
interprets the value of temp dose an infusion rate, has an upper limit of 4 µg/kg/min given
that the error is below 5% of target CO (Error < 5% target CO).
The VisSim block diagram of the second controller can be seen on Figure 2.6.
When the error is above 5% of target CO than a pulse is generated holding the magnitude
for 30 seconds. The magnitude of the pulse is dependent on the criteria outlined above.
If after 30 second from the start of the pulse, the error continues to be above 5% target
CO, than another pulse is called (the magnitude is updated). If anytime during a pulse the
error drops below the 5% target CO, than after 30 seconds from beginning of the pulse an
infusion rate starts. The incrementing of the infusion rate stops either when the error has
gone below 2.5% of target CO or if it has risen above 5% target CO (pulse generated
again). These distinct paths and limitations makes it easy to see how PID output is
controlled and adjusted before administration as a drug dose.
Another interesting observation with the PID controller is that it outputs negative
numbers as well. This occurs when an overshoot is observed in the CO response. This is
not practical for drug delivery systems. Therefore the dose is given a lower limit of zero
for both bolus and infusion rate administrations to block the negative PID output. It is
this second controller that prevents dramatic output responses from occurring due to
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overdosing. The importance of the second controller will be made obvious as a
comparison is done between cascade controller output and PD output in the chapter 4.

2.4 Interfacing Three Models
All three models now discussed, the focus of the section is how their input and output
interface to give the closed loop drug delivery system. Since the focus here is on CHF
patients, the cardiac output is expected to be much below target with no drug present in
the body. Therefore as the simulation starts, the cardiac output is below the upper limit
set for the hysteresis, thus allowing the cascade-controlling system to administer
milrinone to the body. PID controller is enabled and its output (via the temp dose
variable block) is fed into the second controller thus providing the drug dose. Milrinone
dose is both the output of the feedback controlling model and the input into the PK
model. Once milrinone dose is feed into the PK model, the milrinone plasma
concentration is obtained. This PK output is input into the physiological model. The
physiological model takes this drug concentration and calculates the response, the output.
The response that is of concern, the cardiac output, is needed for the input (error cardiac
output) back into the feedback controlling model, and thus making the closed loop drug
delivery controlling system. (Figure 2.7)
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Figure 2.7 Block diagram representation of the closed loop drug delivery system. All
three models are accounted for: milrinone PK model, physiological model, and feedback
controlling model

CHAPTER 3
UNDERSTANDING DYNAMICS
This chapter concentrates on understanding and comparing the pharmacokinetic and
hemodynamic responses of a single intravenous (IV) bolus administration of milrinone of
a simulated CHF patient to a simulated normal patient. On the same note the results
obtained from the simulated models are compared to studies done on human patients to
confirm that the simulated models behave as the patient would under milrinone
administration. The physiological model of the normal patient was obtained from the
research done by Gu [12]. To do this study the feedback controlling model was disabled,
leaving the milrinone PK model attached to the physiological model. Therefore these
two interfacing parts can be referred to as an open loop dynamic model. (Figure 3.1)

Figure 3.1 Block diagram of open loop dynamic model used to test the dynamics of the
system

In understanding the dynamics of the system, CHF patient model responses are
compared to normal patient model responses. Prior to simulating these results, it is
essential to develop a pharmacokinetic model for a, normal patient. There is a small
amount of research available focusing on the pharmacokinetic behavior of milrinone on
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normal patients. Of the research available, a two compartment PK model for milrinone is
used to fit the pharmacokinetic data for the normal human patients.
Therefore when comparing the dynamics of a CHF patient model to a normal
patient model, our results would not be valid because a three compartment PK model is
used in one case (CHF patient) while a two compartment PK model is used in the other
(normal patient). Two compartment and three compartment PK models do not provide
the same dynamic output. This can be seen in the two-three compartment comparisons
for CHF patient model for a 50 and 75 µg/kg doses.(Table 3.1)

Table 3.1 Comparison of a two and three compartment milrinone pharmacokinetic model
for CHF patient model using a 50 and 75 µg/kg bolus dose administration

The solution here is to switch to a two compartment PK model for CHF patient model
thereby allowing a valid comparison to the normal patient model dynamics. Only in this
chapter is milrinone pharmacokinetics defined by a two compartment model. This is done
primarily due to the lack of available research on milrinone pharmacokinetics for normal
patients. The rest of the work uses the three compartment milrinone PK model for CHF
patients as discussed in chapter 2.
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A two compartment PK model for CHF patient model was obtained using
Butterworth's [14] research done on the pharmacokinetic evaluation of milrinone in CHF
patients. The rate constants were calculated from known volumes and clearances as
discussed in Sec 2.2. A two compartment milrinone PK model for simulated normal
patient was obtained through research done by Stroshane.[20] Stroshane provided the
true coefficients (A,B) and exponents (a, j3) for various doses. The rate constants were
calculated using a pharmacokinetic conversion file available through pkpd.icon.paloalto.med.va.gov.[21] The relationship between the model parameters that make it

possible to calculate the rate constants is outlined in the following equations. [13]

The mean of the resulting rate constants was used to obtain the two compartment
milrinone PK model for healthy patients as shown in the appendix, Figure A2
After baseline hemodynamics were obtained (CO and MAP), the IV bolus doses
were administered to the patient models. Four different IV bolus doses were given to
both simulated models (CHF and normal) and responses were recorded. A 25 µg/kg,
50 µg/kg, 75 µg/kg, and 100 µg/kg IV bolus doses were administered to both models.
Milrinone plasma concentration, cardiac output (CO) and mean arterial pressure (MAP)
were recorded over a period of five and half hours after drug administration. There was a
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delay of 60 seconds before the drug was administered and the bolus was given over a
period of 60 seconds as seen in Figure 3.2.

Figure 3.2 Bolus administration of milrinone that is used for the dynamic study

3.1 Phamacokinetic Analysis
The pharmacokinetics of milrinone was studied following a single IV bolus
administration. Figure 3.3 and Figure 3.4 is a display of plasma milrinone concentration
after the IV bolus administration as a function of time. Figure 3.3 is of the normal
patient model. Figure 3.4 is of the CHF patient model. Bolus administration of
milrinone rapidly increases milrinone plasma concentration. Maximum milrinone
concentrations differed significantly among the four bolus doses for both normal and
CHF patient models. Maximum milrinone concentrations for normal patient model are
170, 340, 511, and 675 ng/ml for the 25, 50, 75, and 100 µg/kg doses, respectively.
Maximum milrinone concentrations for CHF patient model are 171, 343, 514, and 686
ng/ml for the 25, 50, 75, and 100 µg/kg doses, respectfully. These results correlate with
previous studies on human patients. Benolti [22] reports peak plasma concentrations of
88 to 454 ng/ml for IV bolus doses of 12.5 to 75 µg/ kg for CHF patients and Stroshane
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Figure 3.3 Plasma concentrations of milrinone as a function of time after intravenous
bolus administration of25, 50, 75, and 100 Jlg/kg doses for simulated normal patient
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Figure 3.4 Plasma concentrations of milrinone as a function of time after intravenous
bolus administration of25, 50, 75, and 100 Jlg/kg doses for simulated CHF patient
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[20] reports 63-640 ng/ml after bolus doses of 10 to 125 µg/kg in healthy volunteers.
Peak plasma concentrations increased with the magnitude of the loading dose and
occurred at the end of the dose in both models. Peak plasma concentrations were
observed at around 117 seconds. Given a delay of 60 seconds before drug administration
and an IV bolus over a 60 second period, 117 seconds is the end of the dose. However
plasma concentrations dissipate rapidly after the loading dose for both patient models.
Milrinone is reported to have clinical efficacy at a threshold concentration of
100ng/ml.[14,23] Clinical efficacy for normal patient model was 6.3, 14.6, 21.9, and
66,8 min and CHF patient model was 7.5, 19.8, 40.7, and 72.7 min for the 25, 50, 75,
and 100 µg/kg dose, respectively. CHF patient results show a slower rate of milrinone
elimination in plasma; therefore the drug maintains efficacy for a longer period of
time.[6] Efficacy data suggests that the 75 µg/kg dose is most effective because there is a
two-fold difference in efficacy time between normal patient and CHF patient model.
Elimination half-life is the time required by the body, tissue, or organ to
metabolize or inactivate half of the amount of the substance taken in. [24] Elimination
half lives often fail to adequately describe the rate of drug disposition of
multicompartment models at clinically relevant drug concentrations.[14] Hughes coined
the term "context-sensitive half time" as a measure of the time needed for the
concentration of the central compartment to decrease in drug concentration by half after
one or more infusions of the drug. Young [6] and Shafer [25] further demonstrated the
usefulness of "context-sensitive" drug disposition and expanded the measure to included
times to concentration reductions greater than 50%. The context-sensitive elimination
times for milrinone are of a greater use to the clinician than the terminal elimination half-
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life. [14] Therefore, milrinone context-sensitive elimination times are calculated for both
patient models. The milrinone two compartment PK model for the normal and CHF
patient models gave context-sensitive elimination times that agreed with previous
research done on human patients. A 1 minute bolus infusion gave mean context-sensitive
elimination times of 6.7, 22.0, and 74.5 min for 50%, 80%, and 90% drug elimination,
respectively, for simulated normal patient. A 1 minute bolus infusion gave mean contextsensitive elimination times of 8.9, 37.8, and 114.9 min for 50%, 80%, and 90% drug
elimination, respectively, for simulated CHF patient. The CHF statistics agreed with
Butterworth's [14] pharmacokinetic analysis, elimination times of 6.7, 41, and 107 min
for 50%, 80%, and 90% drug elimination were observed. Due to the lack of available
literature on milrinone administration on healthy volunteers, context-sensitive elimination
times were not compared to previous research. But the results confirm that milrinone is
eliminated at a quicker rate in healthy subjects than in CHF subjects. These results
correlate with studies done on the elimination half-life of milrinone in healthy and CHF
patients. Following IV administration of milrinone to 21 healthy subjects, a mean
elimination half-life of 0.8 hours was recorded.[20] In another study that concentrated on
CHF patients, the elimination half-life of milrinone after IV bolus doses of 12.5 to 75
µg/kg was 2.3 hours.[6] These studies emphasize that milrinone is maintained in the
blood for a longer duration of time in patients suffering from a failing heart rather than in
healthy, normal volunteers
Another measurement that was recorded was the percentage of plasma milrinone
elimination five and half hours after drug administration. The overall results again
confirmed that milrinone plasma elimination occurred at a slower rate for CHF patient.

38

Table 3.2 Pharmacokinetic response of intravenous bolus administration of milrinone for
simulated normal and CHF patient

than for normal patient. The overall % elimination of milrinone five and half hours after
bolus administration was 99.8% and 98.4% for normal and CHF patient models,
respectively. Milrinone pharmacokinetic analysis is summarized in Table 3.2. But the
100 µg/kg statistics for normal patient do not behave as the other doses. Graphical
representation (Figure 3.3) as well as analysis (Table 3.2) shows that after 50%
elimination it takes longer for the 100 µg/kg dose to be eliminated from the body when
compared to CHF results.

3.2 Hemodynamic Analysis
Cardiac output and mean arterial pressure were monitored five and half hour after drug
administration. Figure 3.5, Figure 3.6, Figure 3.7, and Figure 3.8 are plots of CO and
MAP as a function of time for the different IV bolus for simulated normal and CHF
patients.
Intravenous administration of milrinone has shown to improve cardiac output for
both normal and CHF patients.[6] This is also evident in this simulated study. For both
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cases there is a dose dependant hemodynamic response as outlined by Young. [6] As the
dose is increased, the maximum cardiac output relative to baseline is increased.
Maximum cardiac output increases to 16.4%, 25.5%, 31.4%, and 34.7% relative to
normal patient model baseline for the 25, 50, 75, and 100 µg/kg doses, respectively.
Maximum cardiac output increases to 31.1%, 58.2%, 79.5%, and 91.6% relative to CHF
patient model baseline for the 25, 50, 75, 100 µg/kg doses. This simulated hemodynamic
data agrees with Young's dose dependant hemodynamic response relationship.
Another thing to note is that maximum cardiac output increases to a higher
percentage relative to baseline for the CHF patient model more so than in the normal
patient model for all four doses. In all four doses the CHF maximum percentage change
of CO relative to baseline is about double of the change in the normal patient model. In
fact, studies done using animal models of experimental heart failure show that there is a
greater cardiac output increase relative to baseline in dogs with induced heart failure than
in normal healthy dogs when similar doses of milrinone were administered. Maximum
percentage change of CO relative to baseline for induced heart failure patient is about
twice that of the normal patient.[6] Both simulated and experimental data show
milrinone to be more effective, in terms of increasing CO relative to baseline, for CHF
comparison to normal patients. The correlation of these simulated results to the available
experimental results, again confirm that both models respond to milrinone administration
in the same manner as reported by previous research.
Effect of milrinone administration on MAP as a function of time for normal and
simulated patients is shown in Figure 3.7 and Figure 3.8, respectively. A drop or
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Figure 3.5 Cardiac output as a function of time after milrinone IV bolus administration
of25, 50, 75, and 100 ~g/kg dose for simulated normal patient
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Figure 3.6 Cardiac output as a function of time after milrinone IV bolus administration
of25, 50, 75, and 100 ~g/kg doses for simulated CHF patient patients
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decrease in MAP is shown for both patient models in the graphical representation. But
data analysis gives an increase in MAP relative to baseline for CHF patient model for the
25 and 50 µg/kg doses, while a decline is observed in the two larger doses. The
percentage change in MAP relative to baseline for the first 3 minutes for simulated CHF
patients is +11.6, +2.4, -11.6, -19.8 for the 25, 50, 75, and 100 µg/kg doses, respectively.
The same statistics for the normal patient model are —14.9, -26.2, -36.0, and —44.2. The
effect of milrinone on MAP (first 3 min recording) for normal patients appears to have
more of a pattern than that of the CHF patient dynamics. MAP is further decreased as
dose is increased for simulated normal patient, but MAP is increased and then decreased
for simulated CHF patients. Benotti [6] administered milrinone intravenously, 12.5,
25.5, 50.0, and 75 µg/kg bolus doses, to nine CHF patients, maximum MAP percentage
change from baseline was +4, +8, -5, and —6. Here again there is a rise in MAP followed
by a decline as dose is increased for CHF dynamics. Therefore the simulated dynamic
results for MAP behave the same when compared to studies done on human patients with
CHF. As for the results for the normal patient model, milrinone is expected to decrease
MAP. The decrease in MAP is more prominent in the larger doses, 75 and 100 µg/kg.
Under clinical conditions it is normal or "safe' to decrease MAP to 70mmHg. Any dose
that drops MAP below this threshold, should not be administered. For CHF model, the
100µg/kg dose exceeds this limit, for normal model both the 75 and the 100 µg/kg dose
exceed the limit. In fact, investigators suggest that there is a plateau response to
intravenous bolus milrinone administration and that doses above 50 and 75 µg/kg tend to
increase cardiac rate or produce significant decline in arterial pressure. [6]
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Another interesting observation made from the plots of MAP vs. time is the behavior of it
after the initial decline (or increase). Both model plots show that after the initial change
MAP quickly begins to stabilize and there is no oscillation evident. In fact at a certain
point in time there is no distinction between the MAP relative to baseline for all four
doses. Specifically, the plot for the normal patient shows a quick decline in pressure
followed by steadying of MAP to baseline. The amount of time it takes MAP to stabilize
for simulated normal patient is 16.9, 29.4, 59.4, and 204.8 min for the 25, 50, 75, and 100
µg/kg dose, respectively. Stabilization time for the 100 µg/kg dose is more than the other
three times together. In fact as the dose is increased the time of stabilization becomes
twice of the previous dose. The MAP for CHF model also behaves in similar manner, but
here MAP stabilizes while slowly decreasing to baseline. The amount of time for
stabilization is 6.5, 10.4, 16.3 and 20.8 min for the 25, 50, 75, and 100µg/kg dose,
respectively. Here there is not a drastic jump between time of stabilization of the doses.
Instead, MAP of later three doses appears the same relative to baseline in about 20
minutes. The 25 µg/kg dose seems to be too small of a bolus administration to have a
distinct effect on MAP. In Butterworth's [14] pharmacokinetic study of milrinone, he

Table 3.3 Hemodynamic response of intravenous bolus administration of milrinone for
simulated normal and CHF patient
Patient
Normal
CHF
Normal
CHF
Normal
CHF
Normal
CHF

% MAP from stable MAP
%CO from
%CO
time (min)
Baseline
Increase(max) Baseline at 5.5hrs
(-)14.9
16.9
0.1
16.4
25 _
6.50.4
(+) 11.6
31.1
(-)26.2
29.4'
25.5
0.5
50
(+)2.4
10.4
0.8
58.2
(-)36.04
59.4
0.1
75 31.4
(-)11.6
16.3
1.2
79.5
(-)44.2
204.8
34.7
3.6
100
20.8
(-)19.8
1.7
91.6

Dose( El g/kg)
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concluded that there are no other significant changes in MAP relative to baseline at any
time in any of the doses studies after several minutes of drug administration.
Likewise, there were no significant differences between the dose groups at any time after
the initial change. The correlation between Butterworth's observation to the simulated
results further make the CHF physiological model an appropriate mathematical
representation of the human response. The simulation results show that hemodynamic
changes are expected to return to baseline at the end of six hours. These results are
summarized in Table 3.3.
These simulated results have characterized the magnitude and time course of the
optimal first dose response to a bolus milrinone in patients with congestive heart failure.
There is a clear dose-dependent response relation, with each successive dose producing
incremental plasma milrinone concentration and hemodynamic effect. Among the four
doses, the 100 µg/kg dose resulted in an unwanted decline in MAP without any wanted
response, therefore this would not be an appropriate loading dose. The 25 µg/kg dose
was to small of a dose to maintain responses for an adequate amount of time. What is left
is the 50 and 75 µg/kg doses. Among these two doses both result positive hemodynamic
response without dropping MAP below 70mmHg. Given a target CO as an increase of
50% of baseline (target CO=4587 ml/min), the 50 µg/kg dose is more appropriate for our
purposes. This dose achieves target CO without unnecessary overshoot. Therefore,
bolus administration for the CLDD model will be limited to 50 µg/kg. Also researchers
performing IV dose range studies have concluded that a 50 µg/kg bolus dose of milrinone
is effective for CHF condition. They further conclude that this dose achieves adequate
hemodynamic efficacy with minimal side effects.

CHAPTER 4
OPTIMIZATION OF PID CONTROLLER
As stated in section 3.3, PID controller is short for proportional, integral, and derivative
controller. These three parameter gains (P, I, and D) dictate the performance of the
controller. Each term opts to maintain minimum error so that the control of CO is stable.
Therefore selection or optimization of the P, I, and D parameter gains is necessary for
stable performance of the controller. This chapter concentrates on selecting the
parameter gain that optimizes the controller. Each parameter gain is changed
individually, keeping the other two constant at values of 0.001, 0.0001, and 0.0001 for
the P, I, and D gains, respectively. The error, cardiac output, and milrinone dose are
monitored for a two-hour control period. The error is given as the difference between the
target cardiac output and the true or observed cardiac output. The aim is to minimize
error thus giving a more stable CO response. Comparisons of the results provide the
information necessary in the selection of the optimal parameter gain in each case. This is
referred to as tuning of the PID controller.
An important reminder is that ND parameters are selected while observing the
outputs due to the cascade controller as a whole. Therefore what is observed is not the
direct results of the PID tuning mechanism, but the responses after the second controller
has adjusted the PID output. The second controller acts to stabilize the output of the PID
controller, preventing overshoot or undershoot of response. What happens is that PID
controller outputs a number to be translated into milrinone dose by the second controller.
Then that dose is fed into the milrinone PK model, therefore providing the responses of
CO due to the drug administration.
45
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4.1 ND Output
The importance of this section is to show why there is a need for a second controller that
adjusts the HD output before it can be implemented as the next dose. This section also
shows how changing individual parameter gains influences the PID output to a greater
extent than the output of the two controllers together. The proportional parameter gain is
increased by a factor of ten, P = 0.00001, 0.0001, 0.001, 0.01, 0.1 ,and l. For each
modification, the PID output is recorded while the controller administers milrinone for a
two hour period. The objective is to observe the changes to the PID controller, thus the
PID output as the P gain is increased and to confirm that the second controller is an
essential part of the controlling mechanism.
Figure 4.1 shows the PR) output as a function of time for each proportional gain
modification. The variation of the HD output as the P gain is increased is obvious in the
plots. The PID output for the plots with P = 0.00001 and P = 0.0001 have very slight
noticeable changes, both output range from —4 to +10. As P in increased further to
0.001, the change of the output becomes more obvious. The PID output is still within the
previous range but the controlling mechanism of the PID controller appears to change as
seen by the initial response to the error. Instead of the constant response of 8.4 for the
first 23 minutes (as seen in the two previous simulations), here ones observes a rapid
increase to 7.6 followed by a decline to 0.3 in 10 minutes. For the remainder of time the
controller's output behavior is similar to the previous runs (P 0.00001, 0.0001) in the
magnitude of the response, but differ in time of the response as seen in Figure 4.1.
Further increases in the P gain shows to have drastic changes on the HD output. A
tenfold change in the P gain produces a tenfold change in the ND output.
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Figure 4.1 Plots of PID output as a function of time when the proportional gain is
increased. These plots show how the behavior of the PID controller changes as P gain is
changed as well as the important of the second controller in the cascade controlling
mechanism
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The MD output ranges from -5 to + 20, -50 to + 200, and -500 to + 2000 for the
proportional gain of 0.01, 0.1, and 1, respectively. One can easily see how the parameter
gains affect the performance of the HD controller and thus understand the importance of
tuning the controller. Given the situation where this RD controller would be
implemented (drug delivery) there must a control on the output, especially since PID
outputs negative values, as well. A negative output is not practical for drug delivery
purposes. Also the large overshoots in PID output will have potential harmful effects in
the clinical situation. In the case of simulation studies, as is done in this thesis, the
system will crash. Therefore a second controller is necessary to administer the milrinone
as bolus and infusion rate without possibility of overdosing. In the same note this
controller minimizes the degree of change of the cascade controller output, milrinone
dose, as the PID parameter gains are modified. Nevertheless the optimization of the HD
controller is performed for each parameter gain. Six different simulation runs were
performed for each parameter gain while keeping the remaining two parameter gains
constant. A seventh additional run was performed for the derivative gain because of the
lack of change in CO response as the gain was modified. The mean of the errors is
shown for all simulation runs in Table 4.1. The three minimum error results for each
parameter were observed in detail in deciding the final parameter gains.

Table 4.1 Lists the mean of the error as parameter gains are changed
P-Gain
0.00001
0.0001
0.001
0.01
0.1
1

Mean
139.4639
136.7297
131.0645
112.3074
127.7208
117.3849

1-Gain
0.00001
0.0001
0.001
0.01
0.1
1

Mean
150.0731
151.4502
158.9349
157.3521
157.3519
157.3518

D-Gain
0.00001
0.0001
0.001
0.01
0.1
1
10

Mean
151.5218
151.4502
151.6583
151.3409
151.9548
151.3915
165.4081

49

4.2 Proportional Gain
From the results given in Table 4.1, P values of 0.01, 0.1, and 1 are observed to have the
minimum mean error from the six simulation trials. To better understand and therefore
select the optimal proportional gain, plots of CO and milrinone dosage as a function of
time were used. Figure 4.2 and Figure 4.3 describe system output responses when P is
changed for milrinone dose and CO, respectively.
Looking at the two plots simultaneously, the following observations can be made.
Milrinone administration differs for each choice of the P gain. Initially a bolus of
50 µg/kg is administered in all three cases. But after that initial bolus, drug administration
changes. For P= 0.01 and 0.1 an infusion rate follows the bolus dose. The infusion rate is
continued until CO has exceeded its overshot boundary. This is evident in the CO plot.
There is an immediate rise in CO due to the initial bolus, but CO begins to decline after
the bolus. The effect of the infusion rate is seen as the CO begins to rise again even when
it is above target. This is not seen for P = 1, because drug administration is stopped after
the initial bolus, only to begin when CO has fallen below the given boundaries. The
effect of this second bolus is observed as the CO quickly begins to rise afterwards. In
this case an infusion rate follows the second bolus which maintains the CO above target.
The behavior of the controller due to the different P gain is hereafter similar in that each
P gain causes an administration of a bolus followed by an infusion rate, but is different
because the drug is administered at a different time. Thus causing the maximums for the
CO to occur at different times within the two hour control period. But towards the last
thirty minutes of the control period, the P = 0.01 gain shows a stabilization of the CO.
For this P gain, the controller better understands what it is monitoring, because it appears
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Figure 4.2 Infusion rate of milrinone for the three proportional gains with mInImum
mean error. The peaks are the bolus doses. The magnitude of the bolus dose is
calculated by multiplying the dose by 30 sec.;) because each bolus is administered over a
30 sec. period

Carmac Output Vs. Time (p-Gain)
5000
4800
4600

.-S=

4400

~

4200

;::;::;

S 4000

'-"

0
U

3800
3600

- - P=O.OI
- - P=O.1
- - P=1
- - Target

3400
3200

eo

3000

0

20

40

60

80

100

120

Time (min)
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to have learned with time how to adjust its output while maintaining CO at the desired set
points. The controller has learned that in decreasing the bolus and following it with an
infusion rate, CO can be maintained within limits. Thus P 0.01 is the choice for
optimal proportional gain.

4.3 Integral Gain
The integral parameter gain was narrowed to I = 0.00001, 0.0001, and .01. These choices
for the integral gain gave the minimum mean error of the six simulation trials. In
deciding upon the optimal integral parameter gain, the CO and the dose are plotted for the
two-hours control period.(Figure 4.4, Figure 4.5) Analysis of these plots helps to better
understand the controlling mechanism of the system and therefore selection of the
optimal I gain can be done.
Unlike the case for the P parameter gain, there is more variation in the dosage
scheme between the three different I gains which then produces different curves of CO in
the two-control period. For I = 0.00001, the controller maintains CO by administering
milrinone mainly as an infusion rate. Instead of constantly stopping and starting drug
administration, here one observes milrinone being given as a small infusion rate. This
also prevents the CO from oscillating between maximums and minimums, instead the CO
is more stable. The initial overshoot of CO is greater than the other two simulations, but
the undershoot is also less and there are a lot less maximums and minimums observed in
the two-hour control period. The only setback is that CO reaches target 15 minutes after
control has begun.
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Figure 4.4 Infusion rate of milrinone for the three integral gains with minimum mean
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multiplying the dose by 30 sec, because each bolus is administered over a 30 sec. period.

Carliac Output Vs. Time (l-Gain)

5000
4800
4600
4400

:5

e

4200

i

4000

o

3800

--

U

3600
- - 1=0.00001
- - 1=0.0001
- - 1=0.1
- - Target CO

3400
3200
3000
0

20

40

60
Time (min)

80

100

120

Figure 4.5 CO as a function of time for the three integral gains with minimum mean
error ,

53

The behavior of I = 0.0001 simulation is similar to I = 0.00001 in that drug is
administered mainly as an infusion rate, only two bolus doses are observed. But the
difference is in the magnitude of the infusion rate. For I = 0.0001, drug is given at a
higher infusion rate when compared to I = 0.00001. This also produces more frequent
stops and starts of milrinone administration. The effect of this can be seen as the CO
moves between maximums and minimums. There are six maximums for CO observed
within the two-hour control period.
The controller's behavior is observed to change to administrations of bolus
followed by infusion rates for I gain at 0.1. The initial bolus is at a greater magnitude,
501.1.g/kg and it is immediately followed by an infusion rate. This prevents CO from
getting below target after the initial overshoot. The administration of drug is mainly
characterized by a bolus followed by an infusion rate. Again there are frequent stops and
starts of drug administration causing oscillations in the CO. There are seven maximums
observed for CO within the control period.
Although stabilization of CO is more evident for I = 0.00001 parameter gain
selection, this gain can not be considered in practical terms. The feedback controlling
models should bring CO to target within five minutes of control time. I = 0.0001 and I =
0.1 satisfies this criteria. But between the two choices, I = 0.0001 parameter gain
maintains CO while producing less maximums and minimums for CO. Therefore I =
0.0001 is selected as the optimal integral parameter gain for the control model.
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4.4 Derivative Gain
The three derivative gains with the minimum mean error were D = 0.001, 0.01, and 1. As
was the case in the P and I gain, the dosage and CO plots were analyzed in deciding upon
the optimal derivative gain. Figure 4.6 and Figure 4.7 are plots of dosage and CO as a
function of time for the two-hour control period. For all three cases, similar magnitudes
of milrinone doses are administered. Milrinone is given as an infusion rate rather than a
bolus dose. There are slight differences observed in milrinone administration for the
three cases in the control period. These differences do not appear to have a major
influence in the CO response. CO is observed to respond in the same manner to the three
doses from D gain of 0.0001, 0.01, I. There are six maximums observed for CO in all
three cases. The magnitude of the maximums for CO is observed to be similar as well.
The CO minimums or the undershoot of CO also occur at the same magnitude as well.
After the first hour of control there is difference evident in time that the controller begins
and stops to administer milrinone for the three simulations. The effect of this is also
observed in the CO response because it increases and decreases at different times. For
D=1, drug is given about one and half to two minutes before the simulations using D gain
of 0.001 and .01. This also delays the rise of CO for these simulations with respect to the
simulation using D = 1.
But when the control mechanism of the three different D gains are compared so
that a selection can be made, one concludes that the modification of the D gain does not
produce vital changes within the milrinone dose output. Table 4.1 listing the mean error
of the CO using seven different modifications to the derivative gain also confirms this
observation. The CO errors for the seven simulations are very close.
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Figure 4.6 Infusion rate of milrinone for the three derivative gains with minimum mean
error. The peaks are the bolus doses. The magnitude of the bolus dose is calculated by
multiplying the dose by 30 sec, because each bolus is administered over a 30 sec. period.
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In other words, the D gain does not influence the performance of the controller. The
controller's behavior is outlined more so by the proportional and integral gain. This is an
indication that a PI controller would be appropriate for milrinone delivery purposes. But
the decision is to keep the PID controller. Even though the derivative of the error factor
does not contribute to the performance of the controller, it does not deteriorate the
performance either. To confirm this conclusion, the CLDD system was simulated using a
PI controller while keeping the P and I parameter gains the same. Figure 4.8 and Figure
4.9 plot the dose and CO during the two hour PI control period. Both plots are observed
to behave similar to plots of dose and CO from Figure 4.6 and Figure 4.7, respectively.
But the decision is to keep the first controller as a MD controller, using D = 0.01 for
optimal derivative gain.
The performance of the controller was observed to be optimal using parameter
gains of 0.01, 0.0001, and 0.01 for the proportional, integral, and derivative gains,
respectively. Further testing of the CLDD system will be simulated using these PID
parameter gains.
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Figure 4.8 Infusion rate of milrinone using PI control. The peaks are the bolus doses.
The magnrtude of the bolus is calculated by multiplying the dose by 30 sec., because each
bolus is a ministered over a 30 sec period.
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CHAPTER 5
TESTING OF THE CLOSED LOOP DRUG DELIVERY SYSTEM
Chapter 3 concentrates on validating the performance of the milrinone PK model and
physiological model together. Four different bolus doses were administered to the CHF
patient model, recording the pharmacokinetic and hemodynamic responses. The results
validate that the behavior is similar to available human studies performed using milrinone
administration. With the validation of the PK and physiological model, as well as, the
optimization of the PID controller, the next step is to test the performance of the
controller under varying situations.
The controller must be able to respond to changes within the system by adjusting
the milrinone dose of the drug. In the previous simulations, CHF model parameters were
kept constant. This is not practical in real situations. In fact a patient's characteristics
can change during the course of drug administration. Also certain patient characteristics
can vary as much as 36 fold from one patient to the next. [261 Therefore the controller
must be able to handle a wide variety of patient types; adjusting the milrinone dose to
meet these changes does this.
The robustness of the cascade controller used in this research was tested under three
different situations. The first test observed the transient response of the cascade
controlling mechanism as the target or setpoint CO was changed. In the second test, the
controller responses were observed as perturbation was achieved by changing the vessel
resistance parameters in the circulatory system in the physiological model. The third test
incorporated randomization into the model, using the elimination rate constant, k 10 , as the
randomizing factor in the system. All three tests were performed to better understand
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controller performance in a more realistic situation. Not only does one patient
characteristics differ from the next, but also the characteristics within the same patient
can change during the course of drug administration. Prior to simulating these test
results, it is essential to simulate the controller responses using the three PID parameter
gains that were chosen to optimize the performance of the cascade controller.

5.1 Controller Output with Optimized PID Gains
The values for the P, I, and D parameter gains that were observed to optimize the
performance of the cascade controller are 0.01, 0.0001, and 0.01, respectively.
Simulation of a two hour control period was performed using these gains. Figure 5.1 and
Figure 5.2 are plots of milrinone dose and cardiac output as a function of time. There is
an initial bolus observed immediately followed by an infusion rate. The effect of this
dose is observed in the CO response: an overshoot is seen initially, then a decline is
evident, finally before decreasing to setpoint, CO makes a U-turn and begins to increase
again. Drug is administered in similar manner within the two-hour period because there
is a bolus followed by an infusion rate given each time drug administration begins.
During the second half of the control period, the controller responds by decreasing the
magnitude of the bolus dose, while increasing the duration of the infusion rate. This
achieves more stability in maintaining CO as observed in Figure 5.2. The CO plot begins
to smooth out during the second half of the control period. In comparison to the
individual simulations for each optimized parameter gain (found in chapter 4), there are
fewer maximums and minimums observed in the CO plot using all three optimized gains,
Figure 5.2.
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Figure 5.1 Infusion rate of milrinone using the PID gains that optimizes· the performance
of the cascade· controller. The peaks are the bolus doses. The magnitude of the bolus
dose is calculated by multiplying the dose by 30 sec, because each bolus is administered
over a 30 sec period.
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of the cascade controller
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Table 5.1 Summarizes controller performance using PID optimized parameter gains

In analyzing the performance of the controller, onset delay, time CO error reached 2.5%
target CO, and overshoot from target CO was monitored each time drug administration
was begun during the two hour control period. Table 5.1 summarizes these results each
time drug administration was started, T_CO is target cardiac output. Onset delay is the
"deadtime" between drug infusion and system response.[4] Figure 5.1 shows four
distinct times milrinone was given. The longest onset delay for that two-hour period is 12
seconds. The overall results from Table 5.1 shows an increase in onset delay as control
time progresses. With time the controller understands how to maintain CO and thus better
to stabilize it by decreasing the amount drug given at one time (bolus) and increasing the
duration of drug administration (infusion rate). It is this decrease in drug magnitude that
causes an increase in onset delay with time because there is less drug available in
compartment 1 at one time therefore delaying system response.
The desired range that the controller is trying to maintain the CO error is within
±2.5% of target CO. Each time drug administration was begun during the two-hour
period, the time it took CO error to reach 2.5% of target CO was recorded. The results
were 22, 20, 22, and 37 sec. for the four times drug administration was given. It takes an
average of 25 sec for the controller to bring the error to the desired range. This shows a
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very responsive controller system, because it takes less than half a minute to bring the
output to the desired error range.
In addition the percentage of overshoot from target CO was recording each time
the drug was begun during the two-hour period. The results are 7.15, 5.01, 5.01, and
4.64% overshoot. The controller responds with an overall overshoot of less than 10%
target CO. Throughout the controller period it is observed that the percentage overshoot
decreases with time, as well. This shows that the controller has learned how to maintain
and better stabilize CO error each time it begins to administer drug as is shown in Figure
5.2. The results from this simulation trial, summarized in Table 5.1, will be used as
reference in analyzing and understanding the performance of the controller during the
three simulation tests.

5.2 Transient Response
The transient response of the controller is observed as the setpoint or target for cardiac
output is changed during the simulation. This section will demonstrate the ability of the
cascade controller to change milrinone dose such that the cardiac output tracks to the new
setpoint. The transient response is observed using step setpoint and ramp setpoint
changes.
The simulation testing for step setpoint changes begins using the original target
CO (50% increase in baseline CO) as the setpoint. Then the target CO or setpoint is
changed in a stepwise manner as shown in Figure 5.4. The setpoint is increased three
times after original setpoint. Each setpoint is held for 30 minutes. The setpoint was
incremented by 55, 65, and 85% of baseline each step increase.

Mlrinone Dose Vs. Time (transient step)
2
1.8
1.6
~ 1.4
~

~

1.2

~

~
~

=

1
0.8

Q

0.6
0.4

0.2

o
o

1000

2000

3000

4000
Time (sec)

5000

6000

7000

Figure 5.3 Infusion rate of milr inone as three step transient response is observed. The
peaks are the bolus doses. The magnitude of the bolus is calculated by multiplying the
dose by 30 sec, bec ause each bolus is administered over a 30 sec. period.
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Figure 5.4 CO as a function of t ime as three step transient response is observed.

64

Therefore there is a 3.33, 6.45, 12.12% increase in setpoint from the previous setpoint
each step increment. Figure 5.3 and Figure 5.4 are plots of the milrinone dose and
cardiac output in the control period. The onset delay for the 55, 65, and 85% of baseline
CO is 5, 15, and 15 sec, respectively. The "deadtime" of the control system increases
between with the first two step changes, but remains the same with the final step change.
Overall the onset delay is less than half a minute, which shows the cascade controlling
mechanism to react quickly to changes in the model. Also the CO error reaches desired
range within 60, 139, and 315 sec after the target CO has been changed. As the
difference between the new setpoint and previous setpoint increases, time to reach 2.5 %
of target CO increase as well. But the percentage of overshoot from target CO decreases
with the three step changes. The overshoot is observed to be 5.00, 3.67, and 2.10% of
target CO for the step changes of 55, 65, and 85% of baseline CO. Although the time it
takes CO error to reach desired range increases with time, the percent overshoot
decreases with time. From the these results it is observed that as the magnitude of the
step change from the previous step change increases; it takes longer for the controller to
reach desired range, but the controller is less likely to overdose as well. The controller
becomes less quick to react to the changes because (1) it takes longer for CO error to
reach 2.5% of target CO, and (2) the overshoot decreases as well. To better understand
these results, a second transient step simulation was performed.
The second transient step simulation involved changing the target CO from
original target (50% of baseline) to 85% baseline CO in one step increment. The purpose
of this simulation was to better investigate if indeed the controller's response deteriorated
as the difference between previous and new target CO increased. Figure 5.5 and Figure
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5.6 are plots of milrinone dose and CO as a function of time. The control was simulated
for one hour; the step change was done half-hour after control was begun. The onset
delay, time for CO error to be within 2.5% of target CO, and the percent overshoot are 1
sec, 61 sec, and 1.47% respectively. These observations counteract the previous
conclusion that as the change between previous and new target CO increases, the
feedback-controlling model becomes less responsive. An onset delay of 1 sec shows that
the physiological model responds quickly to controller input of drug. From Figure 5.5 a
large (50µg/kg) bolus administration is observed to track CO to the new setpoint. Give
the magnitude of a bolus administration, there is more drug available within that 30 sec
period for the physiological system to respond. In the case where target CO was
incremented from 50 to 85% of baseline in three step increments, an increase in onset
delay is observed as step changes occur because controller administers smaller bolus
doses (less drug available within the 30 sec bolus administration period). This causes a
delay in system response relative to the case where setpoint is incremented from 50 to
85% of baseline in one step increment. The controller chooses between a bolus and an
infusion rate, and furthermore the magnitude of the bolus after the error has been
analyzed; this is explained in detail in section 2.3. Therefore it is observed that the choice
of the magnitude of the bolus dose affects the onset delay.
Also CO error reaches 2.5 % target CO in about one minute. Unlike the previous
three-step increment to 85% baseline CO, it takes 1/5 of time for CO error to reach
desired range in this one step increment. This also is attributed to the magnitude of the
bolus dose administration. The larger bolus brings CO error within desired boundaries
quickly relative to the small bolus administration. The percentage overshoot of CO from
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Figure 5.5 Infusi on rate of milrinone as one step transient response is observed. The
peaks are the bollu s doses. The magnitude of the bolus is calculated by multiplying the
dose by 30 sec, be cause each bolus is administered over a 30 sec period.
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Figure 5.6 CO as a function of time as one step transient response is observed.
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target is also less, it is observed to be 1.47%. In Figure 5.6 the controller shows to
quickly maintain CO to the new setpoint by adjusting milrinone dose without causing
excessive overshoot.
In both transient step changes from 50 to 85% of baseline CO (3-step increment, 1
step increment), the controller is observed to adjust to new target by responding with a
change in milrinone dose. Depending on how much of a transient step change has
occurred, the controller responds accordingly. On an average the controller begins to
administer drug 22 sec after the change for setpoint has been made. Also when
comparing the onset delay of the transient response to the onset delay with no change to
the system, Table 5.l, the controller maintains transient step control. In addition, the
percentage overshoot is observed to decrease each time transient step change occurred
within the two-hour control period for the three transient step simulation test.
Transient control showed the controller to be robust in maintaining CO at the new
setpoint when incrementing in stepwise manner. An additional transient control
simulation was performed where the target was ramped from r o to a constant value over a
period of 7 min, ro is given 50% of baseline and the constant value is given as 85% of
baseline. VisSim ramp block was used to increment the setpoint using a slope of 2.5.
The ramp block creates a unit ramp signal based on simulation time. The ramp block is
expressed as y = slope* (t- elay).
td

The setpoint was limited to constant value by the use of

VisSim limit block. The VisSim block diagram representation can be seen is Figure 5.7.

Figure 5.8 and Figure 5.9 are plots of milrinone dose and cardiac output during the one
hour control period. The setpoint is ramped after 30 min of control as seen in Figure 5.9.
An onset delay of 4 sec is recorded prior to the initial response of the system.
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Figure 5.7 VisSim block diagram representation of ramped target CO transient response

To maintain CO to the changing setpoint the controller continuously administers small
bolus followed by an infusion rate as shown in Figure 5.8. The drug administration is not
stopped as target is ramped. The administration of the small bolus dose and infusion
rates is evident in Figure 5.9, because there are peaks observed in CO as it is increased
with the ramped target CO. The controller begins to administer milrinone 46 sec after the
initial target CO change. In comparison to the step change, 22 sec, it takes longer for the
controller to respond to the ramped change. Also, from Figure 5.9, it is observed that CO
does not overshoot. But after the seven minutes of ramped signal, when target CO has
reached the constant value, it takes 116 sec for CO error to be within the 2.5% target CO
range. The results of the step and ramped transient control are summarized in Table 5.2.
From both the plots and the result table the controller proves to respond to changes in the
CO target by adjusting the infusion of milrinone. The CO is observed to be maintained
within set boundaries without an oscillatory behavior. Therefore this test shows the
controller to be robust in monitoring and controlling CO by milrinone infusion.
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Figure 5.8 Infusion rate of milrinone as ramped transient response is observed. The
peaks are the bolus doses. The magnitude of the bolus is calculated by multiplying the
dose by 30 sec, because each bolus is administered over a 30 sec. period.
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Figure 5.9 CO as a function of time as ramped transient response is observed.
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Table 5.2 Summarizes the transient response of the cascade controller as target CO
(T

is changed

5.3 Perturbation
This second simulation test observes the effects caused as perturbation or a disturbance is
achieved by changing the resistance parameters in the circulatory system in the
physiological model. The resistances of the following are changed: systemic capillaries,
venules, vena cava, pulmonary capillaries, and pulmonary venules. All resistance
parameters are changed by the same factor. A two-hour simulation test was performed to
test the effect of resistance disturbance. Changes to the simulation were as follows. In
the first half-hour the system ran with no change (disturbance). In the second half-hour
all resistance parameters were reduced to half of the original values. In the third half
hour parameters were set back to their original values. In the final half hour the
resistance parameters were increased to twice the original value. Figure 5.10 and Figure
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5.11 are plots of milrinone dose and cardiac output during the changes of the resistance

parameters.
The first half-hour the system was simulated using the original values for the
resistances in the circulatory system, hence there was no change in the system. Change
or perturbation was introduced to the system the second half-hour, the resistances were
reduced by half. With a reduction in the resistance of the circulatory system, the blood is
able to circulate through the body easier using the same or weaker contractile force from
the heart. There is less strain on the heart because it does not have to work as hard.
Producing an increase in cardiac output and therefore there is less, if any, need for drug
administration. This is evident between 30 and 60 minutes of control as shown in Figures
5.10 and 5.11. When reduction in circulatory resistance is made CO immediately rises
above target CO. Since CO is above target CO, cascade controller stops milrinone
administration. Figure 5.11 There is no drug administration during this half hour
therefore obtaining values for onset delay and time CO error reached set range were not
applicable during this period. An overshoot of 14.23% percent was observed. This
overshoot is not a direct cause of the controller response after the disturbance because no
drug was given at this period. Instead it is caused by the drug that was available in the
body before the disturbance and more importantly the CO increase that occurred due to
the lowering of circulatory resistances. .
At the start of the second hour resistances are set back to their original values.
This returns CO below target. Controller begins milrinone administration in response to
the change. The onset delay and the time taken for CO error to reach 2.5% of target CO
are 15, and 50 sec.
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Figure 5.10 Infusion rate of milrinone as perturbation is achieved by changing the vessel
resistances of the circulatory system. The peaks are the bolus doses. The magnitude of
the bolus is calculated by multiplying the dose by 30 sec~ becau se each bolus is
administered over a 30 sec. period.
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Figure 5.11 CO as a function of time as perturbation is achieved by changing the vessel
resistances of the circulatory system.
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The onset delay agrees with previous simulation test results in Table 5.1. The time for
error to reach the 2.5% boundary again shows the controller to quickly adjust drug
infusion to changes in the system.
The fourth and final half-hour, perturbation is again achieved by increasing
circulatory resistances by twice the original value. With an increase of these resistances,
blood is expected to circulate using a stronger contractile force from the heart. Cardiac
output decreases. More strain on the heart exists causing an increase in demand of drug
administration as seen in Figures 5.10 and 5.11. The results of the perturbation test
simulations are seen in Table 5.3. An increase in the resistance immediately drops CO
below target, the controller responds by adjusting milrinone dose. The onset delay of the
system after the disturbance has been introduced is 13 sec. The controller begins drug
administration with an initial bolus dose of 50 µg/kg. This bolus dose brings the CO
error within 5 to 10% of target CO. The controller continues to administer drug at
maximum small bolus doses (10 µg/kg). Milrinone is administered as continuous bolus
doses, in fact it appears to be a better representation of an infusion rate. The magnitude
of the small bolus dose appears to be insufficient in bringing error CO within 2.5% of
target CO during the half-hour, although the controller is maintaining CO in a stable,
smooth curve. The controller is administering drug at the maximum magnitude
(10 µg/kg) but it appears that this dose (given when 5% target CO < CO error < 10%
target CO) fails to bring CO error within 2.5% of target CO. Indeed as the resistances are
doubled, the performance of the controller drastically degrades because the controller
fails to bring CO within set boundaries, if not target CO. The controller is working at its
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Tables 5.3 Summarizes controller performance as circulatory vessel resistances
(perturbation)

are changed CO

full potential as is seen in Figure 5.10. Given that the CO error falls between 5 and 10%
of target CO the controller can administer small bolus dose with maximum magnitude of
10 µg/kg. From the milrinone plot it us observed that the controller continuously
administers maximum bolus doses so that CO reaches the desired setpoint. Although the
controller is successful in both increasing and stabilizes CO, the CO increase does not
reach the desired target range. This reduction in the performance of the controller is due
to the magnitude of the limit for the small bolus dose rather than the cascade controlling
mechanism itself. The cascade controller is successful in responding to the disturbance
by increasing the administration of drug as well as maintaining a stabile or smooth CO
response. It is the limit of 10 µg/kg bolus dose that prevents the CO from rising to target
in reasonable amount of time (5 minutes). In addition the limit set for the infusion rate
might also prevent CO from rising to target CO in necessary time.
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5.4 Randomization
Randomization is the third change in the system that is done in understanding the
performance of the controller in realistic situations. The third test is performed by
randomizing the elimination rate constant, k 10 , as a two hour control period is simulated.
This simulation test can represent the situation where a patient characteristics change
during the administration of the drug. Four simulation runs are performed. The rate of
drug elimination is changed every one minute and five minutes under set standard
deviation (25% and 50% of original value) and mean (original value).
Randomization of k10 is achieved with the use of VisSim gaussian random
generator block. The gaussian block creates a normally distributed random signal. The
original vale of k10 was chosen as the mean and the value was randomized using standard
deviation (1) 25% and (2) 50% of the original value. Each value was held for one minute
and five minutes before a next guess was made. Minimum of one-minute samples was
chosen because anything smaller would cause the value to change too quickly for any
effect to be noticed. In the case where the values are randomized and held for less than a
minute, the change would be too quick to effect the system. Because the value of k10
would change to rapidly for the system to notice the change and thus be effected by the
change. Since k10 would oscillate some standard deviation from the original value, the
change would be so quick that the system would be effected by the mean of the changed
values: that value being approximately the original k 10 . The k10 guess was sampled and
held with the use of VisSim sampleHold block. The VisSim pulseTrain block was input
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Figure 5.12 VisSim block diagram of randomizing elimination rate constant,k10

into the sampleHold block that determines how long the signal is held. The pulseTrain
block produces a sequence of unit amplitude pulses separated by zeros. [271 The signal,
the other input into sampleHold block, is the random guess for k10. The VisSim block
diagram representation can be seen in Figure 5.12.
Four randomization tests were simulated; (1) standard deviation (STD) = 25% of
original value of k 10 , 1 minute hold, (2) standard deviation (STD) 25% of original value
of k 10 , 5 minute hold, (3) standard deviation — 50% of original value of k 10 ,1 minute hold,
and (4) standard deviation = 50% of original value of k 10 , 5 minute hold. The onset
delay, time CO error reached 2.5% of target CO, and percentage overshoot of CO from
target were recorded each time the controller began milrinone administration during the

Figure 5.13 plots the randomization of k10 using a standard deviation of 25% of original
value and guess is held for one minute before next guess is made
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Figure 5.14 Infusion rate of milrinone as klO is held for 1 min with a standard deviation
of 25% of original value. The peaks are the bolus doses. The magnitude of the bolus is
calculated by multiplying the dose by 30 sec, because each bolus is administered over a
30 sec period.
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25% of original value
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two hour control period for each simulation trial. The plot that shows how k1 0 is
randomized using a 25% of original value as STD and holding the guess for 1 minute is
shown Figure 5.13. This plot shows how indeed randomly the next guess for k

10

is made,

there is no set pattern. In other words there is no mechanism for the controller to prepare
for the next guess, therefore the controller has to continually adjust to the change. This is
a good representation of how patient response to drug can vary within the drug
administration. Figure 5.14 and 5.15 are plots of milrinone dose and CO in the
controlling period as k 10 is randomized. Table 5.4 summarizes the observations from this
simulation. The onset delay each time drug was given is within 2-12 sec range that was
observed when simulating the system under no changes using optimized gains, Table 5.1.
The average time it takes for the CO error to reach within the 2.5% target CO range is 22
minutes. The average for this simulation, 22 sec, not only agrees with the reference
average value of 25 sec, but is less as well. Also the percentage overshoot is observed to
decrease each time drug administration is begun during the control period. It is observed
to be 7.15, 5.16, 5.18, 5.07, and 5.03% for the six distinct times milrinone was given.
There is an overall decrease in CO overshoot.
Table 5.4 Summarizes controller performance as k10 is held for 1 min with a standard
deviation of 25% of original value. T CO is target CO
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Figure 5.16 Plots the randomization of k 10 using a standard deviation of 25% of original
value and guess is held five minute before next guess is made

The pattern agrees with percentage overshoot observation outlined in Table 5.1. The
elimination rate constant is again randomized with a STD of 25% of original value but
here the guess is held for five minutes before the next guess is made, Figure 5.16. The
plots for milrinone dose and CO during the control period for this simulation test as
shown in Figure 5.17 and 5.18, respectively. Table 5.5 outlines the analysis made from
these plots. The onset delay ranges from 2-15 sec. The average time taken for CO error
to reach 2.5% of target CO is 24 min. The percentage overshoot of CO from target for
the six distinct times of drug administration is 7.15, 5.01, 5.03, none, 5.14, and 4.02%.
The results for the onset delay, time taken to reach desired setpoint, and percentage
overshoot corresponds to results observed in Table 5.1. The randomization of k10 using
a STD of 25% of original value for both the one and five minute value hold shows that
the controller's performance does not deteriorate as randomization is incorporated into
the system.
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Figure 5.17 I nfusion rate of milrinone as k lO is held for 5 min with a standard deviation
of 25% of oriiginal value. The peaks are the bolus doses. The magnitude of the bolus is
calculated by' multiplying the dose by 30 sec.::t because each bolus is administered over a
30 sec period
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Figure 5.18 C O as a function of time as k lO is held for 5 min with a standard deviation of
25% of origirnal value
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Table 5.5 Summarizes controller performance as k10 is held for 5 min with a standard
deviation of 25% of original value. T CO is target CO

A third simulation test was performed using a STD of 50% of the original value
and the guess was held for one minute. Figure 5.19 is a plot of k10 as it is randomized
during the simulation. The plots of milrinone dose and CO during the control period are
shown in figure 5.20 and 5.21, respectively. Table 5.6 is a summary of the observations
from the simulation. The onset delay ranges from 2-16 sec for the five times milrinone
administration was given. It takes an average 28.4 sec for the CO error to reach the
desired setpoint. The percentage overshoot is observed as 6.82, 5.08, 5.03, 5.01, and
4.64% for the five times drug is begun.

Figure 5.19 Plots the randomization of k10 using a standard deviation of 50% of original
value and guess is held one minute before next guess is made
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Figure 5.20 Infusion rate of milrinone as klO is held for 1 min with a standard deviation
of 50% of original value. The peaks are the bolus doses. The magnitude of the bolus is
calculated by multiplying the dose by 30 sec, because each bolus is administered over a
30 sec period
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Figure 5.21 CO as a function of time as klO is held for 1 min with a standard deviation of
50% of original value
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Table 5.6 Summarizes
controller performance as k10 is held for 1 min with a standard
50%

Analysis of these results again confirm that randomization does not degrade the
performance of the controller. Comparison of these results to results obtained when
simulating model without incorporating a change, Table 5.1, proves this.
The final simulation was performed again using a STD of 50% of original value
while the guess was held for five minutes before next guess was made, Figure 5.22.
Figure 5.23 and 5.24 are plot of milrinone dose and CO during the control period as the
elimination rate constant is randomized. Table 5.7 summarizes the results of the
simulation trail. Unlike the previous simulations, milrinone administration was begun
two times in the two hours. The onset delay for the both administrations was 2 sec.

Figure 5.22 Plots the randomization of k10 using a standard deviation of 50% of original
value and guess is held five minute before next guess is made
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Figure 5.23 Infusion rate of milrinone as k lO is held for 5 min with a standard deviation
of 50% of original value. The peaks are the bolus doses. The magnitude of the bolus is
calculated by multiplying the dose by 30 sec., because each bolus is administered over a
30 sec period
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Figure 5.24 CO as a function of time as k lO is held for 1 min with a standard deviation of
50% of original value
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It took an average of 16.5 sec for CO error to reach set boundary. Milrinone
administration results in a CO overshoot of 7.21 and 1.91%. The CO plot, Figure 5.24, is
a visible representation of the how the controller maintains a smooth and stable CO
response toward the second half of the control period. The onset delay results again
confirm with Table 5.1 listing onset delay time between 2 and 12 sec. The average time
taken for CO error to be within range is less than 25 sec reference value. And finally the
percentage overshoot behaves similar to previous results; it is observed to decrease with
time.

Table 5.7 Summarizes controller performance as klo is held for 5 min with a standard
deviation of 50% of original value. T CO is target CO

The findings from the randomization simulation studies performed using the rate
constant k10 as the randomizing factor prove that the controller can maintain CO
response to set boundaries by adjusting drug infusion when a parameter in the system is
continuously varied during the control period. The results for each simulation were
compared to simulation results obtained in sec 5.1, the case where system was simulated
when no change had occurred. The behavior of randomization of the elimination rate
constant models the patient varying pharmacokinetic response of eliminating the drug
from the blood. These simulations monitor the cascade controller performance given a
simulated condition of how a patient response or characteristics can vary within the drug
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administration. All simulation results confirm that the controller can adjust milrinone
infusion to maintain CO response within setpoint limits as a parameter is varied with
time. In fact, in the four simulation studies, the controller was observed to bring CO
error to setpoint range in less than half a minute. This result shows a very responsive and
quick controlling mechanism. In addition there was a decreasing pattern observed for the
percentage overshoot of CO in all simulations. Here it is observed that the controller
goes through a learning process in the controlling period because it can better maintain a
smooth and stable CO response with time.
The three simulation tests, transient response, perturbation, and randomization,
helped to better understand the performance of the cascade controlling mechanism using
to monitor cardiac output of congestive heart failure patients by milrinone infusion. On
the same note, the results convey the robustness of the controller as well as the necessary
refinements.

CHAPTER 6
CONCLUSION AND RECOMMENDATIONS
The objective in this thesis was the design and testing of a simulated closed loop drug
delivery system. The focus was the administration of milrinone used to maintain cardiac
output for congestive heart failure patients. The CLDD system consists of a
pharmacokinetic model, physiological model, and feedback-controlling model.
Prior to simulating the controller's performance in maintaining CO, system
dynamics were observed. An analysis of system dynamics was observed to see if an open
loop CHF patient model responded to milrinone administration in the same manner as
available experimental data. The open loop dynamic model (milrinone PK, and
physiological model) was simulated as four different bolus doses were given. In addition
to comparing CHF open loop dynamic model results to available experimental data, an
open loop dynamic model was simulated for a normal patient as well. Simulation results
of "context- sensitive" elimination times, efficacy time, CO response, and MAP response
confirm that the behavior of the open loop dynamic model is similar to experimental
research available for CHF patients under milrinone administration. Therefore the open
loop dynamic model of the CHF patient is an accurate representation of clinical situation.
This open loop model can be further used to understand the responses of varying dose
regimens of milrinone. In addition to understanding the appropriate bolus administration
in achieving a certain response, research can be done on effects of different infusion rates
of milrinone as well. In fact this model can be used to describe the best combination of
bolus and infusion rate of milrinone in obtaining a desired response. The focus in the
dynamic study was on milrinone plasma concentration, CO response, and MAP response.
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The focus can also be extended to include the effect of milrinone on heart rate, systolic
arterial pressure, diastolic arterial pressure, contractile force, etc. With additional
responses monitored, one gets a better picture of the effects of milrinone administration
on the CHF patient. Since the simulated observations from milrinone plasma
concentration, CO response, and MAP response agree with previous clinical studies,
there is more room available for further simulated analysis of milrinone administration
for CHF patients.
After the validation of the open loop dynamic model, optimization of PID
parameter gains was performed. The optimized gains were chosen as 0.01, 0.0001, and
0.01 for the P, I, D gain, respectively. The variation of the parameter gains did not show
drastic differences in maintaining CO because the second controller adjusted the Pm
output and fed it into the PK model as a milrinone dose. Instead there were obvious
changes observed in the PID controller output, rather than the cascade controller output.
But the analysis was done to obtain minimum CO error as PID parameters were
modified. Therefore the means of choosing the optimized PID parameter gains were
sufficient.
Dynamic analysis and optimization of the PID controller led into the testing of the
simulated CLDD system. The CLDD system underwent three tests, observing the
controller performance in maintaining CO for each test. The results were compared to
the simulation test of the CLDD system using optimized parameter gains; these results
are referred to as the reference simulation test.
The most successful of the three tests was the randomization of the elimination
rate constant during the two hour controlled drug administration. Success was measured
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primary by how long it took controller to bring CO error to within 2.5% of target CO and
what the percentage overshoot of CO was each time drug administration was begun
during the control period. During randomization of k10, the controller brought the CO
error within set boundaries in less than half a minute and a decreasing pattern was evident
for the percent overshoot. Both of these observations confirm with the results of the
reference simulation. Therefore the controller maintained its performance as a drug
elimination rate was varied throughout the control. Its controlling mechanism did not
deteriorate due to the incorporation of a randomizing factor. To further validate these
findings, additional rate constants can be randomized as responses are recorded. Also
randomization should be further implemented into parameters of the physiological model.
This simulation test looked into the controller's response as a pharmacokinetic parameter
was continuously modified. The results confirm the cascade controller's ability to
continuously adjust to the changing PK model and therefore an expansion can be made to
the parameters that can be randomized, leading into further understanding of the
controller and of the CLDD system as a whole.
The observations of the remaining two tests show the controller to be robust in
maintaining CO by adjusting milrinone infusion. The results of the transient response and
perturbation tests are in common in the sense that the controller's performance degrades
at certain times within the controller period. The controller's performance is not
deteriorated by the fact that it can not adjust to the change in the system. But the
performance is deteriorated by how quickly the controller can bring CO error within the
set range. From the plots in sec 5.2 and 5.3 it is observed that although the controller
fails to bring CO to set boundaries, it is administering drug at the maximum magnitude
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(controller is working at its full potential). This shows that the controller is aware of the
difference between the target CO and the true CO, and thus is continuously
administrating milrinone at the maximum magnitude specified by the second controller
given how far the error is from target. Therefore it is realized that the deterioration of
controlling mechanism is not to blame on the cascade controller, but its decay lies in the
magnitude limits set for the drug administration. Specifically, the limit of the small bolus
doses (10 µg/kg) given when CO error is between 5- 10% of target CO contributes to the
performance degradation. A solution would be to increase the magnitude of the small
bolus, but this would also introduce an increase in CO overshoot when the error lies in
the lower portion of the range. A better solution would be to increase the available paths
that the PID output can take before being fed into the PK model as milrinone dose. In
other words refinement of the second controller is necessary. Presently, the second
controller takes the PID output and implements it either as a larger bolus with a limit of
50 µg/kg, a small bolus with a limit of 50 µg/kg, or an infusion rate with a limit of
4 µg/kg/min. The distinction between what path the PID output will take depends on how
far the CO error is from the target CO. Further system dynamic study is necessary in
understanding exactly what magnitudes of bolus and infusion rate administration are
necessary to bring the CO to the required setpoint range. Then the second controller can
better understand what magnitude of drug administration is necessary in quickly
maintaining CO response to the target. Therefore there would be more appropriate paths
for the PID output to take before fed in as a milrinone dose. This refinement in the
system will also improve the overall response of the controller, not just when it fails to
bring CO to the setpoint in the necessary amount of time (5 minutes). Aside from this
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weakness in the CLDD system, the controller performance matched the performance of
the reference simulation test.
The CLDD system model was tested under three varying conditions. The overall
performance of the controller maintains the output response to the setpoint by adjusting
the infusion of the drug. But along the way limitations of the system were observed and
thus refinement was necessary. In this thesis, as is the case in many other theses, what is
important is not that the student's research has brought about a sufficient solution to what
he/she has tried to develop or understand, but that the student grasps an understanding of
the limitations and thus realizes the necessary refinement to his/her thesis. In doing so
the end result is not only developing the simulated CLDD system, but also understanding
how it can be improved to better meet the performance requirements. Therefore this
thesis involves the development, testing, and room for improvement of a simulated closed
loop drug delivery system used to control the infusion of milrinone for congestive heart
failure patients. In addition it leads to the possibility of the development of an automated
milrinone infusion system used to maintain CO for patients suffering from CHF.

APPENDIX

Figure Al VisSim block diagram of hysteresis compound block
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Table A2 Intravenous milrinone pharmacokinetic data for healthy Patients
Patient

Dosage(mg/kg)
1

k10

10
10 10
30
30
30
45
45
45
60
60
60
75
75
75
100
100
100
125
125
125

2

3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
MEAN

k21
k12
0.0491
0.0944
0.065
0.1512
0.1025
0.068
0.041
0.0681
0.0535
0.077.
0.0939
0.0471
0.059
0.0807
0.0508
0.053'
0.0833
0.0471
0.068
0.0721
0.0353
0.056
0.0554
0,036
0.057
0.067
0.0426
0.067
0.0821
0.039
0.063
0.0806
0.0425
0.071
0.0417
0.0749
0.03.
0.019
0.0171
0.0406
0.073
0.0888
0.0669
0.057
0.0366
0.0086
0.032
0.012
0.047
0.0452
0.0269
0.0145
0.0171
0.029
0.0467
0.073
0.047
0.0121
0.034
0.0144
0.023
0.0115
0.024
0.053238095 0.064147619 0.038942857
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